Drug Pipeline for Macular Degeneration in Focus at AAO

Updates from phase 3 trials of VEGF inhibitors for neovascular age-related macular degeneration, and a novel genetic treatment, will be highlighted at the American Academy of Ophthalmology meeting.
Medscape Medical News

Full Story →